Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Revisiting the Hunt Hess Scale: Evaluation after EVD placement better predicts mortality
Neuro Trauma, Critical Care, and Sports Neurology
P16 - Poster Session 16 (5:30 PM-6:30 PM)
13-002
To determine whether there is a difference in hospital mortality among high grade subarachnoid hemorrhage patients (Hunt Hess (HH) grade of 4-5) based on whether or not their neurologic exam improves in the first three days after external ventricular drainage (EVD).

Traditionally, higher HH grade has been associated with worse outcomes; grade 4-5 patients have reported mortality rates of 24 and 71% respectively. EVD placement is a common procedure to treat acute hydrocephalus after aSAH and may be associated with early neurologic improvement. It is unknown whether patients who experience neurologic improvement after EVD placement have different outcomes than those who do not improve.
Retrospective analysis of all poor grade (HH4-5) aSAH treated at a single academic center from September 2018 – October 2019. Those who did not receive EVD were excluded. A total of 24 patients were included. Clinical improvement was defined as documented command following up to post-EVD day 3. Primary outcome was in-hospital mortality. Secondary outcomes included discharge destination and need for ventriculoperitoneal shunt (VPS). Fisher’s exact test was used to assess associations between categorical variables.
Of 24 patients, 58% improved (n=14) and 42% did not (n=10). Patients with clinical improvement, compared to those without, had significantly lower mortality 21% vs 80%. Patients with clinical improvement were 12.65 times less likely to die (p=0.01). Among survivors, 9/11 (81.8%) in the group that had neurologic improvement were ultimately discharged to home or acute rehab compared to 1/2 (50%) in those without improvement. VPS was required in 7/13 (53.8%) of those who survived in both groups.
Among high grade aSAH patients, there appear to be two phenotypes – one that has rapid neurologic improvement after ventricular drainage, and another that does not. Patients who demonstrate early improvement after EVD placement have significantly lower mortality than those who do not.
Authors/Disclosures

PRESENTER 		No disclosure on file
Kaitlin Reilly-Kit, MD (Hackensack University Medical Center) Dr. Reilly-Kit has nothing to disclose.
John Liang, MD (Mount Sinai Health System) Dr. Liang has nothing to disclose.
No disclosure on file
No disclosure on file
Alexandra S. Reynolds, MD Dr. Reynolds has nothing to disclose.
Neha Dangayach, MD, FÂ鶹´«Ã½Ó³»­ (Icahn School of Medicine At Mount Sinai and Mount Sinai Hospital) Dr. Dangayach has nothing to disclose.
Christopher P. Kellner, MD (Mount Sinai Health System) Dr. Kellner has stock in METIS Innovative. Dr. Kellner has stock in Precision Recovery. Dr. Kellner has stock in Synchron. Dr. Kellner has stock in Fluid BioMed. Dr. Kellner has stock in Proprio. Dr. Kellner has stock in Von Vascular. Dr. Kellner has stock in E8. Dr. Kellner has stock in Borvo. Dr. Kellner has stock in Phantom Neuro. Dr. Kellner has stock in Radical. Dr. Kellner has stock in Reach Neuro. Dr. Kellner has stock in Aurenar. The institution of Dr. Kellner has received research support from Integra. The institution of Dr. Kellner has received research support from Penumbra. The institution of Dr. Kellner has received research support from Viz.AI. The institution of Dr. Kellner has received research support from ICE Neurosystems. The institution of Dr. Kellner has received research support from Irras. The institution of Dr. Kellner has received research support from Microtransponder. The institution of Dr. Kellner has received research support from Medtronic. The institution of Dr. Kellner has received research support from Longeviti. The institution of Dr. Kellner has received research support from Endostream. The institution of Dr. Kellner has received research support from CVAID.
No disclosure on file
Neha Dangayach, MD, FÂ鶹´«Ã½Ó³»­ (Icahn School of Medicine At Mount Sinai and Mount Sinai Hospital) Dr. Dangayach has nothing to disclose.